On January 20, 2025, GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is excited to announce that one late-breaking oral presentation and six posters presentation will be released at the 2025 Muscular Dystrophy Association (MDA) Conference. The conference will take place from March 16-19th, 2025 at Hilton Anatole, Dallas, TX.
Oral Presentation:
- Title: A Clinical DMD Cytosine Base Editing Drug
This late-breaking abstract highlights the latest progress and clinical potential of our transformative base editing drug GEN6050X targeting Duchenne Muscular Dystrophy (DMD) patients amenable to exon 50 skipping. As the first human application of a base editing drug in DMD, this study marks a significant milestone in treating DMD by gene editing.
Poster Presentations:
These posters will cover a broad spectrum of cutting-edge research related to base editing drug approach, providing insights into the advancements in preclinical efficacy and safety evaluations, off-target assessments for the base editing drug, the design of AAV vectors and novel AAV capsid screening.
MDA Clinical and Scientific Conference
The MDA Clinical and Scientific Conference is an international conference focused on advancing neuromuscular disease research and care. This premier event brings together clinicians, researchers, industry leaders, and patient advocates to discuss the latest breakthroughs in neuromuscular medicine. With cutting-edge research and innovative therapies on the horizon, the conference offers unparalleled opportunities to engage with leaders in the field and shape the future of treatments and cures for neuromuscular diseases.
More information is available on the MDA website https://www.mdaconference.org/
